By Stine Jacobsen, Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Novo Nordisk's top investor moved to take control of the drugmaker's board on Tuesday, vowing a sharper focus on the key U.S. market to revive sales of blockbuster weight-loss drug Wegovy as Novo's chair and six independent board members quit. The non-profit Novo Nordisk Foundation, which combines business ownership with philanthropy, said it would propose its own chair Lars Rebien Sorensen - a former Novo CEO - to le ...